Bipiperidinyl derivatives of 23-hydroxybetulinic acid reverse resistance of HepG2/ADM and MCF-7/ADR cells.

Abstract:

:Multidrug resistance (MDR) is a major obstacle to successful chemotherapy for cancer; thus, novel MDR reversers are urgently needed. In the present study, we assessed whether two synthetic derivatives of 23-hydroxybetulinic acid, 3,23-O-diacetyl-17-1,4'-bipiperidinyl betulinic amide (DABB) and 3,23-O-dihydroxy-17-1,4'-bipiperidinyl betulinic amide (DHBB), could reverse MDR induced by ATP-binding cassette (ABC) transporters. Using the MTT assay, we found that DABB and DHBB could enhance the cytotoxicities of ABCB1 substrates doxorubicin, vincristine, and paclitaxel in ABCB1-overexpressing HepG2/ADM and MCF-7/ADR cells, whereas that of a non-ABCB1 substrate cisplatin was unaffected. The ABCB1 substrate accumulation and efflux assay showed that DABB and DHBB not only enhanced the retention of doxorubicin and rhodamine123 but also inhibited the efflux of rhodamine123. Further mechanistic studies by reverse transcription PCR, western blot, and ABCB1 ATPase activity assay indicated that DABB and DHBB suppressed ABCB1 ATPase activity, but did not alter mRNA or protein expression of ABCB1. ABCB1 siRNA pretreatment attenuated the reversal effect of DABB and DHBB, indicating that their reversal effects were partially dependent on ABCB1. Docking analysis also implied that DABB and DHBB bind directly to ABCB1 at a site partly overlapped with that of verapamil. Taken together, our findings suggest that two bipiperidinyl derivatives of 23-hydroxybetulinic acid reverse ABCB1-mediated MDR through modulation of ABCB1 ATPase activity, thereby inhibiting its efflux function in both HepG2/ADM and MCF-7/ADR cells. These findings may contribute toward the development of novel MDR reversers using DABB and DHBB as adjuvant anticancer chemotherapy.

journal_name

Anticancer Drugs

journal_title

Anti-cancer drugs

authors

Zhang DM,Li YJ,Shu C,Ruan ZX,Chen WM,Yiu A,Peng YH,Wang J,Lan P,Yao Z,Fung KP,Fu LW,Chen ZS,Ye WC

doi

10.1097/CAD.0b013e32835fcc77

subject

Has Abstract

pub_date

2013-06-01 00:00:00

pages

441-54

issue

5

eissn

0959-4973

issn

1473-5741

journal_volume

24

pub_type

杂志文章
  • A suramin derivative induces enterocyte-like differentiation of human colon cancer cells without lysosomal storage disorder.

    abstract::Suramin is a polysulfonated naphthylurea currently investigated for the treatment of advanced malignancy. We have previously reported that suramin was a potent inducer of the differentiation of the human colic adenocarcinoma cell clone HT29-D4 (Fantini et al., J Biol Chem, 1989; 264: 10282-10286). In this report, we s...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199010000-00011

    authors: Baghdiguian S,Nickel P,Marvaldi J,Fantini J

    更新日期:1990-10-01 00:00:00

  • Pharmacokinetics and central nervous system toxicity of declopramide (3-chloroprocainamide) in rats and mice.

    abstract::Declopramide (3-chloroprocainamide) has been identified in previous studies as a representative of a new class of chemosensitizers. In this study, the toxicity and pharmacokinetics of declopramide have been investigated and compared with a structural analog, metoclopramide (MCA). Declopramide has not induced central n...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199901000-00010

    authors: Hua J,Pero RW,Kane R

    更新日期:1999-01-01 00:00:00

  • Doxycycline and other tetracyclines in the treatment of bone metastasis.

    abstract::The tetracycline family includes tetracycline, doxycycline and minocycline, all of which have been used as antibiotics effectively for decades. New uses emerged for these compounds after their effect on mitochondrial function was discovered. Cytostatic and cytotoxic activity of these compounds was shown against cell l...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/00001813-200311000-00001

    authors: Saikali Z,Singh G

    更新日期:2003-11-01 00:00:00

  • Extravasation accidents with liposomal/liposomal pegylated anthracyclines treated with dexrazoxane: an overview and outcomes.

    abstract::The extravasation of chemotherapeutic agents is a challenge for oncologic care teams. The management of nonliposomal (conventional) anthracyclines is well established in clinical practice guidelines, including general measures and specific antidotes, such as dexrazoxane. However, there is little scientific evidence on...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/CAD.0000000000000672

    authors: Caballero Romero Á,Delgado Ureña MT,Salmerón García A,Megías Fernández MT,Librada Porriño-Bustamante M,Cabeza Barrera J

    更新日期:2018-10-01 00:00:00

  • Chitosan nanoparticles for dermaseptin peptide delivery toward tumor cells in vitro.

    abstract::The present study aimed to entrap and characterize the morphology and antitumor effects of a dermaseptin (DStomo01) peptide in chitosan nanoparticles, in vitro. DStomo01 nanoparticles showed moderate polydispersivity, excellent colloidal stability, and slow release. It was noted that free DStomo01 induced DNA fragment...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000052

    authors: Medeiros KA,Joanitti GA,Silva LP

    更新日期:2014-03-01 00:00:00

  • Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel.

    abstract::Docetaxel is a new antimicrotubule agent that induces a predominantly sensory neuropathy that is mild in most patients. This prospective study was performed to determine if corticosteroid co-medication reduces the incidence and severity of docetaxel-induced neuropathy. Two groups of patients treated with docetaxel in ...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1097/00001813-199810000-00003

    authors: Pronk LC,Hilkens PH,van den Bent MJ,van Putten WL,Stoter G,Verweij J

    更新日期:1998-10-01 00:00:00

  • The relationship between the antitumor activity and the ribonucleotide reductase inhibitory activity of (E)-2'-deoxy-2'-(fluoromethylene) cytidine, MDL 101,731.

    abstract::(E)-2'-deoxy-2'-(fluoromethylene) cytidine (MDL101,731) is a new deoxycytidine analog which shows potent antitumor activity against several human tumor models. We previously showed that MDL101,731 inhibited human ribonucleotide reductase (RNR) in HeLa S3 human cervical carcinoma cells. Recently, it has been reported t...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199808000-00011

    authors: Kanazawa J,Takahashi T,Akinaga S,Tamaoki T,Okabe M

    更新日期:1998-08-01 00:00:00

  • Apoptosis induced by desmethyl-lasiodiplodin is associated with upregulation of apoptotic genes and downregulation of monocyte chemotactic protein-3.

    abstract::There is growing interest in the discovery of bioactive metabolites from endophytes as an alternative source of therapeutics. Identification of their therapeutic targets is essential in understanding the underlying mechanisms and enhancing the resultant therapeutic effects. As such, bioactive compounds produced by end...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e3283635a47

    authors: Hazalin NA,Lim SM,Cole AL,Majeed AB,Ramasamy K

    更新日期:2013-09-01 00:00:00

  • Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.

    abstract::Anomalous gene regulation, dictated by epigenetic modifications, is a universal characteristic of cancer cells. Histone deacetylases (HDACs) are an important class of enzymes that influence gene expression by the removal of acetyl groups from histones leading to chromatin remodeling and transcriptional suppression of ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/CAD.0b013e32833dad91

    authors: Jazirehi AR

    更新日期:2010-10-01 00:00:00

  • High incidence of coagualopathy in phase II studies of recombinant tumor necrosis factor in advanced pancreatic and gastric cancers.

    abstract::This multi-center trial was carried out to assess the therapeutic potential of recombinant tumor necrosis factor (rTNF) as the first form of systemic therapy for advanced carcinomas of gastric and pancreatic origin. To be eligible patients were required to have no overt sign of coagulopathy and hepatic function studie...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1097/00001813-199206000-00002

    authors: Muggia FM,Brown TD,Goodman PJ,Macdonald JS,Hersh EM,Fleming TR,Leichman L

    更新日期:1992-06-01 00:00:00

  • Galloyl cyclic-imide derivative CH1104I inhibits tumor invasion through suppressing matrix metalloproteinase activity.

    abstract::Matrix metalloproteinase (MMP)-2 and MMP-9 have been associated with the ability of tumor cells to metastasize because of their capacity to degrade type IV collagen, the main component of basement membrane, and to their elevated expression in malignant tumors. (S)-methyl 6-(benzyloxycarbonylamino)-2-(2-((S)-2,6-dioxo-...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e328313e15b

    authors: Chen MH,Cui SX,Cheng YN,Sun LR,Li QB,Xu WF,Ward SG,Tang W,Qu XJ

    更新日期:2008-11-01 00:00:00

  • A clinical armamentarium of marine-derived anti-cancer compounds.

    abstract::The sea, covering 70% of the Earth's surface, offers a considerably broader spectrum of biological diversity than terra firma. Containing approximately 75% of all living organisms, the marine environment offers a rich source of natural products with potential therapeutic application. Marine organisms have evolved the ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:

    authors: Jimeno JM

    更新日期:2002-05-01 00:00:00

  • Activation of c-Jun N-terminal kinase is required for mevastatin-induced apoptosis of salivary adenoid cystic carcinoma cells.

    abstract::Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase, originally developed for lowering cholesterol. Statins also have pleiotropic effects, independent of cholesterol-lowering effects, including induction of apoptosis in various cell lines. However, the mechanism underlying statin-induced apoptosi...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:

    authors: Zhang S,Wang XL,Gan YH,Li SL

    更新日期:2010-08-01 00:00:00

  • Novel mechanisms involving chemically modified tetracycline 3 cytotoxicity.

    abstract::Chemically modified tetracycline 3 (CMT-3) is a potential anticancer drug because of its retained matrix metalloproteinases inhibitory property. In the present study,we showed that CMT-3 significantly inhibited the growth and proliferation of human hepatocellular carcinoma HepG2 cells. Novel mechanisms including incre...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/cad.0000000000000144

    authors: Zhao L,Xu J,Jiao Y,Wang H,Fan S

    更新日期:2014-11-01 00:00:00

  • Docetaxel: an interesting new drug for the treatment of head and neck cancers and soft tissue sarcomas.

    abstract::Results are summarized for two phase II studies of docetaxel as first-line therapy for advanced squamous cell carcinoma of the head and neck (SCCHN) and one study of docetaxel as second-line therapy for advanced soft tissue sarcomas. In all three studies, docetaxel was administered at a dose of 100 mg/m2 by intravenou...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1097/00001813-199507004-00004

    authors: Verweij J

    更新日期:1995-07-01 00:00:00

  • Metformin sensitizes human bladder cancer cells to TRAIL-induced apoptosis through mTOR/S6K1-mediated downregulation of c-FLIP.

    abstract::Metformin, an oral antidiabetic agent, has been reported to potentiate chemotherapeutic-induced cytotoxicity. In this study, we investigated the effects and molecular mechanisms of metformin in sensitizing tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human bladder cancer cells. ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000116

    authors: Zhang T,Wang X,He D,Jin X,Guo P

    更新日期:2014-09-01 00:00:00

  • Triterpenoids as new promising anticancer drugs.

    abstract::Triterpenoids are structurally diverse organic compounds, characterized by a basic backbone modified in multiple ways, allowing the formation of more than 20 000 naturally occurring triterpenoid varieties. Several triterpenoids, including ursolic and oleanolic acid, betulinic acid, celastrol, pristimerin, lupeol, and ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/CAD.0b013e328330fd90

    authors: Petronelli A,Pannitteri G,Testa U

    更新日期:2009-11-01 00:00:00

  • A randomized trial of two schedules of trimetrexate versus 5-fluorouracil in advanced colorectal cancer: a Southwest Oncology Group study.

    abstract::Trimetrexate (TMQ), a non-classical folate antagonist, was studied in a randomized controlled trial in patients with advanced colorectal cancer and without prior chemotherapy. Patients were randomly assigned to one of three treatments: TMQ at 200 mg/m2 i.v. q 2 weeks, TMQ at 12 mg/m2 i.v. daily x 5 or 5-fluorouracil (...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00001813-199504000-00004

    authors: Brown TD,Fleming TR,Goodman PJ,Macdonald JS,Pugh RP,O'Rourke T

    更新日期:1995-04-01 00:00:00

  • A case of glassy cell carcinoma of the uterine cervix effectively responding to chemotherapy with paclitaxel and carboplatin.

    abstract::Glassy cell carcinoma (GCC) of the uterine cervix is a highly malignant tumor and has a poor prognosis. As yet, no effective systemic chemotherapy to this tumor has been reported. Here we describe a case of recurrent GCC that responded to paclitaxel and carboplatin combination treatment. The patient, a 32-year-old wom...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200108000-00010

    authors: Hirashima Y,Kobayashi H,Nishiguchi T,Miura K,Kanayama N

    更新日期:2001-08-01 00:00:00

  • Development of transferrin-modified poly(lactic-co-glycolic acid) nanoparticles for glioma therapy.

    abstract::Glioma is a primary intracranial malignant tumor with poor prognosis. In this study, we aimed to develop transferrin (Tf)-modified poly(lactic-co-glycolic acid) (PLGA) nanoparticles to deliver temozolomide (TMZ) to glioma and evaluate their efficacy to kill glioma. TMZ-loaded nanoparticles were prepared by nanoprecipi...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000754

    authors: Mao J,Meng X,Zhao C,Yang Y,Liu G

    更新日期:2019-07-01 00:00:00

  • Effect of dolastatin 10 on human non-Hodgkin's lymphoma cell lines.

    abstract::It is crucial to incorporate new and more potent antineoplastic agents in treating non-Hodgkin's lymphoma since standard chemotherapy fails to cause a significant increase in the survival rate. A potential chemotherapeutic agent is dolastatin 10; hence, the objective of our study is to investigate the effect of the an...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199605000-00016

    authors: Maki A,Mohammad R,Raza S,Saleh M,Govindaraju KD,Pettit GR,al-Katib A

    更新日期:1996-05-01 00:00:00

  • Structure-activity studies on gossypol in tumor cell lines.

    abstract::Gossypol [(2,2'-binaphthalene)-8,8'-dicarboxaldehyde-1,1',6,6',7,7'-hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl] 1a is a naturally occurring compound extracted from the cotton plant and has been extensively studied as an oral male contraceptive. Its favorable toxicity profile, and the more recent demonstration of anti-...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200003000-00009

    authors: Shelley MD,Hartley L,Groundwater PW,Fish RG

    更新日期:2000-03-01 00:00:00

  • Gemcitabine plus cisplatin chemotherapy with concurrent para-toluenesulfonamide local injection therapy for peripherally advanced nonsmall cell lung cancer larger than 3 cm in the greatest dimension.

    abstract::Para-toluenesulfonamide (PTS), active ingredient being PTS, is a new anticancer drug applied through local intratumoral injection. The aim of this phase II clinical trial was to investigate the response and toxicity of standard gemcitabine (GEM) plus cisplatin (CIS) chemotherapy with concurrent intratumoral injection ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e32832fe48f

    authors: He J,Ying W,Yang H,Xu X,Shao W,Guan Y,Jiang M,Wu Y,Zhong B,Wang D,Tucker S,Zhong N

    更新日期:2009-10-01 00:00:00

  • Intensive cisplatin/oral etoposide for epithelial ovarian cancer: the Cambridge Gynae-Oncology Centre experience: too toxic for relapse?

    abstract::Intensive cisplatin and oral etoposide for relapsed epithelial ovarian cancer (EOC), commonly known as the van der Burg (VDB) protocol, has been reported to improve response rates and progression-free survival. We report on all patients with relapsed EOC treated on the VDB protocol at the Cambridge Gynae-Oncology Cent...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000320

    authors: Gounaris I,Iddawela M,Parkinson C,Pratt J,Hatcher H,Basu B,Tan LT,Brenton JD,Earl HM

    更新日期:2016-03-01 00:00:00

  • Growth inhibition and apoptosis induction of human melanoma cells by omega-hydroxy fatty acids.

    abstract::We examined the anti-tumor activity and structure-activity requirements of omega-hydroxy fatty acids (omega-HFAs) on the human melanoma cell line G361. The omega-hydroxystearic acid (omega-HSA) had strong growth-inhibiting and cytotoxic activity. Although omega-hydroxypalmitic acid (omega-HPA) also had growth-inhibiti...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200506000-00010

    authors: Abe A,Sugiyama K

    更新日期:2005-06-01 00:00:00

  • Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine.

    abstract::Hemolytic uremic syndrome (HUS) is a rare clinical and biological entity. HUS has been reported after several anticancer chemotherapies and most often after mitomycin C-based chemotherapy regimens. Little information is available concerning the occurrence and outcome of this syndrome after administration of more recen...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199907000-00004

    authors: Gross M,Hiesse C,Kriaa F,Goldwasser F

    更新日期:1999-07-01 00:00:00

  • Cellular cytotoxicity and in-vivo biodistribution of docetaxel poly(lactide-co-glycolide) nanoparticles.

    abstract::Docetaxel (DTX) is one of the most effective antineoplastic drugs. However, its current clinical administration, formulated in tween80, causes serious side effects. This study is focused on preparation and evaluation of poly(lactide-co-glycolide) nanoparticles (NPs) containing DTX to remove tween80. Drug encapsulation...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e328331f934

    authors: Esmaeili F,Dinarvand R,Ghahremani MH,Ostad SN,Esmaily H,Atyabi F

    更新日期:2010-01-01 00:00:00

  • Inhibition of c-myc in breast and ovarian carcinoma cells by 1,25-dihydroxyvitamin D3, retinoic acid and dexamethasone.

    abstract::The role and regulation of the c-myc protooncogene in breast and ovarian neoplasms is receiving increased attention. The downregulation of the c-myc protooncogene by 1,25-dihydroxyvitamin D3 (calcitriol), retinoic acid (RA) and dexamethasone (Dex) is closely associated with growth inhibition in leukemic cells. Calcitr...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199304000-00012

    authors: Saunders DE,Christensen C,Wappler NL,Schultz JF,Lawrence WD,Malviya VK,Malone JM,Deppe G

    更新日期:1993-04-01 00:00:00

  • Phase I-II evaluation of intravesical novantrone (mitoxantrone) in superficial bladder cancer.

    abstract::The objective of this study was to determine the safety and efficacy of intravesical novantrone in refractory superficial bladder cancer. The eligibility criteria included proven carcinoma in situ or superficial transitional cell carcinoma of the bladder at stage Ta or T1 that was proven refractory to or in relapse af...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章

    doi:10.1097/00001813-199104000-00005

    authors: Sharifi R,Lee M,Clayton M,Lamb D,Siami P,Strub M,Albert D,Sarosdy M

    更新日期:1991-04-01 00:00:00

  • A retrospective study of paclitaxel combining nedaplatin chemotherapy for esophageal cancer.

    abstract::The aim of this study was to evaluate the efficacy and tolerability of the combination of paclitaxel and nedaplatin in patients with advanced esophageal cancer. Patients (n = 310) with recurrent or metastatic esophageal squamous cell carcinoma, who had a maximum of one previous chemotherapy regimen, were enrolled in t...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000170

    authors: Du J,Hu C,Zhang Y,Hu B,Wang F,Zhang Y

    更新日期:2015-01-01 00:00:00